When volatility strikes the stock market as it sets new highs, investors get nervous. Wild swings in price can often signal a market top. After setting a new record high last month, the S&P 500 has peeled back 5% from that level. A string of upcoming economic indicators coming out this week could determine whether the economy is heading into a recession or if the Federal Reserve will cut interest rates. Stocks are flailing to and fro as investors try to gauge the direction. Yet analysts at Bank of America ( ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 | --- | --- | |---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------| | | | | If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new ...

Day One Biopharmaceuticals, Inc. (DAWN) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.67. This compares to loss of $0.61 per share a year ago. These figures are adjusted for non-recurring items. Day One Biopharmaceuticals, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $8.19 million for the quarter ended June 2024, surpassing the Zacks Consensus Estimate by 810.22%. This compares to zero revenues a year ago. W ...

Exhibit 99.1 Entered into a definitive agreement for an oversubscribed private placement of its securities for total gross proceeds of approximately $175 million Company to host conference call and webcast today, July 30, 8:00 a.m. Eastern Time BRISBANE, Calif., Jul. 30, 2024 – Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) ("Day One" or the "Company"), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today ann ...

Entered into a definitive agreement for an oversubscribed private placement of its securities for total gross proceeds of approximately $175 million Expanded pipeline with DAY301, potential first-in-class Antibody Drug Conjugate (ADC) targeting PTK7 About Day One Biopharmaceuticals Day One Biopharmaceuticals believes when it comes to pediatric cancer, we can do better. The Company was founded to address a critical unmet need: the dire lack of therapeutic development in pediatric cancer. Inspired by "The Day ...

Expanded pipeline with DAY301, potential first-in-class Antibody Drug Conjugate (ADC) targeting PTK7 Entered into a definitive agreement for an oversubscribed private placement of its securities for total gross proceeds of approximately $175 million BRISBANE, Calif., July 30, 2024 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) ("Day One" or the "Company"), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threaten ...

The private placement includes participation from both new and existing investors including Fairmount, Braidwell LP, Deerfield Management, Wellington Management, Frazier Life Sciences and Access Biotechnology, as well as large investment management firms and several healthcare dedicated funds. J.P. Morgan, TD Cowen, Goldman Sachs & Co. LLC and Piper Sandler are acting as joint placement agents for the private placement. About Day One Biopharmaceuticals Day One is based in Brisbane, California. Forward-looki ...

BRISBANE, Calif., July 30, 2024 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) ("Day One" or the "Company"), a commercial-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced it has entered into a securities purchase agreement for an oversubscribed private placement of its securities for gross proceeds of approximately $175.0 million, before deducting placement agent fees and ...

Day One Biopharmaceuticals (DAWN) signed an exclusive licensing agreement with MabCare Therapeutics for exclusive worldwide rights to develop, manufacture and commercialize the latter's investigational candidate, MTX-13 (now DAY301), for solid tumor indications. Shares of the company gained 11.3% on Jun 18, in response to the encouraging news. It is important to note that the investigational new drug application for DAY301 received FDA clearance in April 2024 based on positive results from its pre-clinical ...

Targets PTK7, highly expressed in broad range of adult and pediatric solid tumors In April 2024, the U.S. Food and Drug Administration (FDA) cleared the investigational new drug (IND) application for MTX-13, which going forward will be identified as DAY301. In pre-clinical studies, DAY301 showed antitumor activity in a wide range of solid tumors. DAY301 targets PTK7, a highly-conserved, catalytically inactive transmembrane protein that is overexpressed in multiple adult cancers, including esophageal, ovaria ...